


**Serial No.:** 09/029,579  
**Filed:** May 6, 1998

The Commissioner is hereby authorized to charge any additional fees owed, or credit any overpayment made to Deposit Account No. 06-1300 (Our File A-66805/RFT/NBC). A copy of this sheet is enclosed for accounting purposes.

Respectfully submitted,

FLEHR HOHBACH TEST  
ALBRITTON & HERBERT LLP

Date: Dec 7, 2001

  
Richard F. Trecartin (Reg. No. 31,801)

Four Embarcadero Center, Suite 3400  
San Francisco, California 94111-4187  
Telephone: (415) 781-1989

**Appendix of Pending Claims**

**Serial No.:** 09/029,579

**Filing Date:** May 6, 1998

**VERSIONS WITH MARKINGS TO SHOW CHANGES MADE**

7. (Amended) A composition for targeting a double stranded nucleic acid and inhibiting replication thereof, wherein said composition comprises an effective amount of a padlock probe oligonucleotide having two free nucleic acid end parts which anneal to two closely adjacent sequences within said double stranded nucleic acid so that the padlock probe is capable of circularization by joining said free end parts and catenating with a target sequence within said double stranded nucleic acid, for inhibition of replication.
8. (New) The composition according to Claim 7 further comprising a pharmaceutical carrier.
9. (New) The composition according to Claim 8, further comprising a linking agent, wherein said linking agent is capable of joining said two free nucleic acid end parts.
10. (New) The composition according to Claim 9, wherein said linking agent is a ligase enzyme.
11. (New) The composition according to Claim 8, wherein said end parts further comprise a mutually chemically reactive compound.
12. (New) The composition according to any one of Claims 7-11, wherein said padlock probe comprises a non-natural nucleic acid or polymer.